BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 33393387)

  • 21. Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence.
    Xu H; Feng H; Zhang W; Wei F; Zhou L; Liu L; Zhao Y; Lv Y; Shi X; Zhang J; Ren X
    Exp Cell Res; 2022 Jul; 416(1):113157. PubMed ID: 35427598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors.
    Hata H; Matsumura C; Chisaki Y; Nishioka K; Tokuda M; Miyagi K; Suizu T; Yano Y
    Cancer Control; 2022; 29():10732748221130576. PubMed ID: 36254804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Fujimoto A; Toyokawa G; Koutake Y; Kimura S; Kawamata Y; Fukuishi K; Yamazaki K; Takeo S
    Thorac Cancer; 2021 Aug; 12(15):2198-2204. PubMed ID: 34173724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.
    Wang W; Gu X; Wang L; Pu X; Feng H; Xu C; Lou G; Shao L; Xu Y; Wang Q; Wang S; Gao W; Zhang Y; Song Z
    Cancer Immunol Immunother; 2022 Jul; 71(7):1693-1703. PubMed ID: 34817639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors.
    Park H; Hatabu H; Ricciuti B; Aijazi SJ; Awad MM; Nishino M
    Eur J Radiol; 2020 Nov; 132():109275. PubMed ID: 32949913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer.
    Cathcart-Rake EJ; Sangaralingham LR; Henk HJ; Shah ND; Riaz IB; Mansfield AS
    Clin Lung Cancer; 2020 Sep; 21(5):421-427.e2. PubMed ID: 32446852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
    Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
    Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors.
    Shibata Y; Murakami S; Kato T
    Expert Opin Drug Saf; 2021 May; 20(5):537-547. PubMed ID: 33650443
    [No Abstract]   [Full Text] [Related]  

  • 33. New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.
    Lin X; Chen X; Long X; Zeng C; Zhang Z; Fang W; Xu P
    Respir Res; 2023 Feb; 24(1):64. PubMed ID: 36849947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19.
    Mellinghoff SC; Vanshylla K; Dahlke C; Addo MM; Cornely OA; Klein F; Persigehl T; Rybniker J; Gruell H; Bröckelmann PJ
    Front Immunol; 2021; 12():798276. PubMed ID: 34987520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.
    Berner F; Flatz L
    Immunol Rev; 2023 Sep; 318(1):37-50. PubMed ID: 37548043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
    Yamamoto T; Ito T; Hase T; Ishigami M; Mizuno K; Yamamoto K; Imai N; Ishizu Y; Honda T; Shibata H; Hatta T; Yogo N; Yasuda S; Toyoda H; Abe T; Kawashima H; Hashimoto N; Fujishiro M
    Cancer Invest; 2022 Feb; 40(2):189-198. PubMed ID: 34658277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis.
    Paderi A; Gambale E; Botteri C; Giorgione R; Lavacchi D; Brugia M; Mazzoni F; Giommoni E; Bormioli S; Amedei A; Pillozzi S; Matucci Cerinic M; Antonuzzo L
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and validation of a risk-prediction model for immune-related adverse events in patients with non-small-cell lung cancer receiving PD-1/PD-L1 inhibitors.
    Qiu Q; Wu C; Tang W; Ji L; Dai G; Gao Y; Chen E; Jiang H; Xie X; Zhang J
    J Zhejiang Univ Sci B; 2023 Oct; 24(10):935-942. PubMed ID: 37752094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.